Newsroom
Official announcements, industry coverage, and media resources from MayMag Biologics.
Tirzepatide Pharm Corp (dba Zeptide Pharma) officially rebrands as MayMag Biologics, reflecting expanded capabilities in 506(e) industrial sterile pharmaceutical manufacturing, biosimilar production, and global distribution partnerships.
Read full release →United Accreditation Management Licensing Services (UAMLS) issues GMP Certificate No. INGM/AN-27354/130977/0626 to MayMag Biologics, covering Insulin Analogs & GLP-1s, Injectable Biologics, 503B & 506E Sterile Drugs, and Clinical IND manufacturing.
Read full release →MayMag Biologics announces scalable industrial 506(e) manufacturing capacity for epinephrine auto-injectors, addressing ongoing FDA drug shortage designations for this critical emergency medication.
Read full release →Pharmaceutical Manufacturing
MayMag Biologics cited as a model for industrial-scale 506(e) outsourcing facilities addressing critical drug shortages in the US market.
October 2026BioPharm International
Industry analysis highlighting MayMag Biologics among the growing cohort of FDA-registered manufacturers scaling GLP-1 and GIP receptor agonist production.
October 2026Drug Discovery & Development
Feature on how 506(e)-registered manufacturers like MayMag Biologics are helping close the global access gap for biosimilar insulin and diabetic drug therapies.
October 2026Journalists, analysts, and media professionals can request our official media kit — including company backgrounder, executive bios, high-resolution logos, and facility photography.
Request Media KitFor press inquiries, interview requests, or media partnerships, please contact our communications team.
press@peptidences.comContact Press Team